Enzymlogic has recently secured a €2.2 million grant from the European Commission and the Spanish Innovation Agency (CDTI) to bring KINETICfinder® to pharmaceutical and biotech companies, allowing them to preselect the drugs with the greatest possibilities to reach the market.
Enzymlogic has recently secured a €2.2 million grant from the European Commission and the Spanish Innovation Agency (CDTI) to bring KINETICfinder® to pharmaceutical and biotech companies, allowing them to preselect the drugs with the greatest possibilities to reach the market.
The European Innovation Council (EIC) supports deep-tech companies to develop and scale-up game-changing innovations through the EIC Accelerator program. The EIC Accelerator is a funding instrument which identify and support breakthrough technologies with the potential to scale up internationally and become market leaders.
Notoriously known as being one of the most competitive and largest public funding programs in the European Union, from the over 5000 top-tier proposals from 21 countries submitted in 2021 only about 300 (less than 6 %) were selected for funding (directly or through the Next Generation EU instrument).
With this funding milestone, Enzymlogic is recognized as one of Europe’s leading innovators in drug discovery services. This support will allow Enzymlogic to take critical next steps in expanding its KINETICfinder® platform to a broader set of protein targets, hire key positions and drive growth in new markets.
About Enzymlogic
Enzymlogic is a world leader in kinetic profiling of compounds to facilitate drug discovery. As experts in the generation and interpretation of kinetic data, we pride ourselves on a proven track record of successful partnerships with worldwide organizations of all sizes, supporting them on a routine basis during the early phases of drug discovery.
We focus on the Hit to Lead (H2L) and Lead Optimization (LO) stages of drug discovery where our optimized kinetic profiling assays identify compounds with therapeutic potential that merit further progression into clinical trials.